
   Additional Secondary and Exploratory End Points Greaterreductionsinfastingserumglucosewereobservedwith all tirzepatide doses vs insulin lispro at week 52 (eTable 7 in Supplement 2). Reductions in mean daily 2-hour postpran- dialglucosefromthe7-pointself-monitoredbloodglucosepro- filerangedfrom65to78mg/dLwithtirzepatidevs65mg/dL withinsulinlispro(eFigure5inSupplement2). An HbA1c target of 6.5% or less was achieved in 56% of tirzepatide-treatedparticipantsand22%withinsulinlisproand anHbA1c targetoflessthan5.7%(exploratoryendpoint)was achieved in 18% of participants in the tirzepatide group and 3% of those in the insulin lispro group (eTable 7 and eFig- ure3BinSupplement2).Fortheefficacyestimand,morepar- ticipantsachievedacompositeendpointofanHbA 1cvalueof lessthan7.0%withoutclinicallysignificanthypoglycemiawith tirzepatide (53%-75%) vs insulin lispro (13%) (eTable 8 in Supplement2). Body weight reduction of at least 5% was met by 62% to 78%ofparticipantsinthetirzepatidegroup(eTable7in Supple- ment2).Bodyweightreductionofatleast10%wasmetby32% to57%andreductionofatleast15%wasmetin13%to37%of thetirzepatidegroup(exploratoryendpoint).